N/A N=84 Spirituality Teaching Program for Depressed Adults
Major Depression
Primary: Hamilton Depression Rating Scale - Depression Severity — 20.4; 20.3; 11.9; 18.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Study of the Validity of Using the MEQ to Measure Mindful Eating in Pregnant Women
Pregnancy
Primary: Test-Retest Reliability of the Mindful Eating Questionnaire (MEQ) — .85 test-retest coefficent
Phase 3 N=961 Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Treatment Day 85 (Visit 8) — 0.172; 0.171 Liters — p=0.964
Phase 2 N=20 A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
Cancer
Primary: Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at…
Phase 4 N=171 Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy
Otitis Media
Primary: Maximum Postoperative Face, Legs, Activity, Cry and Consolability (FLACC) Pain Score. — 2.9; 2.7; 2.0 units on a scale — p=0.21
N/A N=282 INTRuST Structured Assessment For Evaluation of TBI (SAFE-TBI)
Brain Injuries, Traumatic
Primary: Test-retest Reliability SAFE-TBI — 0.372; 0.504; 0.581 kappa (reliability)
N/A N=488 A Comparative Study of Papacarie® and the Conventional Method for Dental Caries Treatment
Dental Caries · Secondary Dental Caries · Personal Satisfaction
Primary: Number of Participants With Treatment Failure — 2; 2 participants
N/A N=110 Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia
Renal Anemia of Chronic Kidney Disease
Primary: Average Observed Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents (ESAs) — 38; 15; 17; 5 hours/year
Phase 3 N=421 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Chronic Myeloid Leukemia
Primary: The Percentage of Patients Achieving MMR by 12 Months — 70.8 percentage of participants
Phase 3 N=1,246 Pharmacogenetics of Nicotine Addiction Treatment
Nicotine Addiction
Primary: 7-day Point Prevalence Quit Rate at End-of-Treatment (EOT) — 17.2; 18.6; 27.7; 22.5 percentage of ITT subjects
Phase 3 N=790 Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Primary: Overall Survival — 57.6; 44.0 months — p=0.0003
Phase 3 N=617 An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
Parkinson's Disease
Primary: Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III — 26.4 units on a scale
Phase 4 N=68 Melatonin in Smoke-induced Vascular Injury
Smoking · Vascular System Injuries
Primary: Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of Fbg. — 2.76; 2.38; 2.89; 2.49 g/L
N/A N=12 Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes
Diabetes Mellitus, Type 1
Primary: Suitability of the Device - Overall Suitability Score — 2.00 units on a scale
N/A N=43 Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion
Leukocytosis
Primary: Percent Decrease in White Blood Cell Count in Patient Following Apheresis Procedure — 54.5 % change in subject's WBC count